Summary
Eli Lilly and Company (LLY) filed an 8-K on July 30, 2019, primarily to report their second-quarter financial results for the period ended June 30, 2019. The key information is contained within an attached press release (Exhibit 99.1), which is being furnished rather than formally filed. Investors should refer to this press release for detailed financial performance data, operational highlights, and any forward-looking statements or guidance the company provided for the second quarter of 2019. While the 8-K itself is a brief notification of the results announcement, the attached press release serves as the critical document for understanding Lilly's performance during the second quarter. This includes revenue figures, earnings per share, and potentially updates on key product sales and pipeline developments that would be of significant interest to shareholders and potential investors assessing the company's current financial health and future prospects.
Key Highlights
- 1Eli Lilly & Co. (LLY) filed an 8-K on July 30, 2019, to announce its second-quarter financial results for the period ending June 30, 2019.
- 2The detailed financial results are provided in an attached press release (Exhibit 99.1).
- 3The information is furnished and not formally filed under Section 18 of the Exchange Act, meaning it's not subject to the same liability provisions.
- 4Investors should consult Exhibit 99.1 for specifics on revenue, earnings, and operational performance.
- 5The filing serves as an official notification of the company's Q2 2019 earnings announcement.
- 6No other material events or new financial statements were disclosed in the 8-K itself, beyond the earnings release.